Latest On BioXcel Therapeutics, Inc (BTAI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-29 08:05 EST | News | BioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 Will | N/A |  |
| 2023-05-25 18:49 EST | News | BioXcel trades lower after mixed results for lower dose Igalmi for bipolar agitation | N/A | |
| 2023-05-22 05:35 EST | News | BioXcel Therapeutics: Clinical Trial Milestones Drive Stock But Slow Market Adoption Persists | N/A | |
| 2023-05-11 17:36 EST | News | BioXcel Therapeutics: It Is All About Key Upcoming Clinical Data Readouts | N/A | |
| 2023-05-08 21:53 EST | News | BioXcel Therapeutics, Inc. (BTAI) Q1 2023 Earnings Call Transcript | N/A | |
About BioXcel Therapeutics, Inc (BTAI):
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorpo read more...rated in 2017 and is headquartered in New Haven, Connecticut.
General
- Name BioXcel Therapeutics, Inc
- Symbol BTAI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 50
- Fiscal Year EndDecember
- IPO Date2018-03-08
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.bioxceltherapeutics.com
Valuation
- Price/Book (Most Recent Quarter) 5.57
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$4.41
- Next Year EPS Estimate -$3.44
- Next Quarter EPS Estimate -$0.98
- Return on Assets -40%
- Return on Equity -70%
- Earnings Per Share -$1.77
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 1.08 billion
- EBITDA -28411000
- PE Ratio -0.23
- Analyst Target Price $113.36
- Book Value Per Share $8.47
Share Statistics
- Shares Outstanding 24.57 million
- Shares Float 15.26 million
- % Held by Insiders 3980%
- % Held by Institutions 53.92%
- Shares Short 3.61 million
- Shares Short Prior Month 3.57 million
- Short Ratio 6.51
- Short % of Float 25%
- Short % of Shares Outstanding 15%
Technicals
- Beta 1.31
- 52 Week High $67.74
- 52 Week Low $14.27
- 50 Day Moving Average 52.38
- 200 Day Moving Average 49.13
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
BioXcel Therapeutics, Inc (BTAI) Dividend Calendar:
BioXcel Therapeutics, Inc (BTAI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
BioXcel Therapeutics, Inc (BTAI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
BioXcel Therapeutics, Inc (BTAI) Chart:
BioXcel Therapeutics, Inc (BTAI) News:
Below you will find a list of latest news for BioXcel Therapeutics, Inc (BTAI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
BioXcel Therapeutics, Inc (BTAI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest BTAI Trades:
BioXcel Therapeutics, Inc (BTAI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-08-14 | 8-K (Current report) | |
| 2020-08-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-31 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-07-31 | 8-K (Current report) | |
| 2020-07-27 | S-3ASR (Automatic shelf registration statement of securities of well-known seasoned issuers) | |
| 2020-07-27 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-07-27 | 8-K (Current report) | |
| 2020-06-24 | 8-K (Current report) | |
| 2020-06-24 | 8-K (Current report) | |
| 2020-06-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-23 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-06-17 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-06-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-26 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-26 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-26 | 4 (Statement of changes in beneficial ownership of securities) | |
BioXcel Therapeutics, Inc (BTAI) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of BioXcel Therapeutics, Inc (BTAI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3980%
Institutional Ownership: 5392%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-02-24 | Krishnan Nandabalan | Director | Sell | 300,000.00 | 30.08 | 9,024,000.00 | 9,180,000.00 | |
| 2020-02-24 | Vimal Mehta | CEO, President and Secretary | Sell | 300,000.00 | 30.08 | 9,024,000.00 | 9,180,000.00 | |
| 2020-02-14 | Frank Yocca | Chief Scientific Officer | Buy | 80,000.00 | 0.41 | 32,800.00 | 88,397.00 | |
| 2019-08-23 | PETER MUELLER | Director | Buy | 1,554.00 | 9.34 | 14,514.36 | 168,320.00 | |
| 2019-08-22 | PETER MUELLER | Director | Buy | 6,646.00 | 8.83 | 58,684.18 | 166,766.00 | |
| 2019-08-21 | PETER MUELLER | Director | Buy | 1,800.00 | 8.42 | 15,156.00 | 160,120.00 | |
| 2019-08-16 | Vimal Mehta | CEO, President and Secretary | Buy | 974.00 | 8.89 | 8,658.86 | 9,957.00 | |
| 2019-08-15 | Vimal Mehta | CEO, President & Secretary | Buy | 2,625.00 | 8.67 | 22,758.75 | 8,983.00 | |
| 2019-08-14 | Vimal Mehta | CEO, President & Secretary | Buy | 358.00 | 8.44 | 3,021.52 | 6,358.00 | |
| 2019-08-13 | Vimal Mehta | CEO, President & Secretary | Buy | 1,000.00 | 8.75 | 8,750.00 | 6,000.00 | |
| 2019-08-13 | Frank Yocca | Chief Scientific Officer | Buy | 6,547.00 | 8.67 | 56,762.49 | 8,397.00 | |
| 2018-12-14 | Vimal Mehta | CEO, President, Secretary | Buy | 800.00 | 4.27 | 3,416.00 | 3,800.00 | |
| 2018-12-14 | Vimal Mehta | CEO, President, Secretary | Buy | 200.00 | 4.32 | 864.00 | 4,000.00 | |
| 2018-12-14 | Vimal Mehta | CEO, President, Secretary | Buy | 500.00 | 4.48 | 2,240.00 | 4,500.00 | |
| 2018-12-14 | Vimal Mehta | CEO, President, Secretary | Buy | 400.00 | 4.49 | 1,796.00 | 4,900.00 | |
| 2018-12-14 | Vimal Mehta | CEO, President, Secretary | Buy | 100.00 | 4.50 | 450.00 | 5,000.00 | |
| 2018-12-07 | PETER MUELLER | Director | Buy | 495.00 | 5.00 | 2,475.00 | 151,415.00 | |
| 2018-12-07 | PETER MUELLER | Director | Buy | 6,905.00 | 5.01 | 34,594.05 | 158,320.00 | |
| 2018-12-06 | PETER MUELLER | Director | Buy | 1,295.00 | 5.00 | 6,475.00 | 150,820.00 | |
| 2018-12-06 | PETER MUELLER | Director | Buy | 100.00 | 5.01 | 501.00 | 150,920.00 | |